Study drug VIR-5818 with and without pembrolizumab
Treatments studied
Part of Cancer clinical trials.
This early trial tests whether VIR-5818 given through a vein is safe and whether it works better when combined with pembrolizumab. It’s for adults with HER2-positive cancers that are locally advanced or spread, and the study checks safety, side effects, and early signs of effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can give informed consent (or your legal representative can).
- Your expected lifespan is at least 12 weeks.
- Your daily functioning is good (ECOG 0 or 1—able to do most usual activities).
- Your cancer must be HER2-expressing, and your doctor must confirm details of the cancer type and prior treatments.
- You should not have major heart or lung problems, or certain recent heart events.
- You should not have major autoimmune diseases that affect organs, or an active ongoing infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
This trial tests a new drug called VIR-5525, either alone or combined with pembrolizumab (an immunotherapy), for people with advanced solid tumors that have not responded to other treatments or cannot undergo standard therapy. It focuses on certain cancer types and tumors with a specific genetic change (EGFR amplification).
This trial tests an experimental drug called ARV-6723, alone or with another drug called pembrolizumab, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these combinations can help shrink tumors or slow their growth.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
Hear when a new Locally Advanced or Metastatic HER2-Expressing Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.